Drug evaluation: Deferitrin for iron overload disorders.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  IDrugs : the investigational drugs journal

• Publication date

  2007-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 17642018
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders.

  2007cited by this paper
• A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

  2007cited by this paper
• Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake.

  2006cited by this paper
• A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

  2006cited by this paper
• The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major.

  2006cited by this paper
• Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.

  2006cited by this paper
• The design, synthesis, and evaluation of organ-specific iron chelators.

  2006cited by this paper
• Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.

  2006cited by this paper
• Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.

  2006cited by this paper
• Survival in thalassaemia major patients.

  2006cited by this paper
• The Design of Orally Active Iron Chelators

  2005cited by this paper
• Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

  2005cited by this paper
• Preclinical and Clinical Development of Deferitrin, a Novel, Orally Available Iron Chelator

  2005cited by this paper
• Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.

  2005cited by this paper
• The design of orally active iron chelators.

  2005cited by this paper
• The Safety and Pharmacokinetics of Deferitrin, a Novel Orally Available Iron Chelator.

  2004cited by this paper
• Metabolic and pharmacokinetic evaluation of a Novel 3-hydroxypyridinone iron chelator, CP502, in the rat

  2004cited by this paper
• Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.

  2003cited by this paper
• Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.

  2003cited by this paper
• Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.

  2003cited by this paper
• Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases

  2003cited by this paper
• DMT1: A mammalian transporter for multiple metals

  2003cited by this paper
• Clinical trial of deferiprone iron chelation therapy in β‐thalassaemia/haemoglobin E patients in Thailand

  2003cited by this paper
• Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.

  2003cited by this paper
• Pulmonary Iron Overload in Thalassemia major Presenting as Small Airway Disease

  2002cited by this paper
• Structure-activity relationships among desazadesferrithiocin analogues.

  2002cited by this paper
• Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.

  2002cited by this paper
• Oral iron chelators--development and application.

  2002cited by this paper
• Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.

  2002cited by this paper
• The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients

  2002cited by this paper
• Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values.

  2001cited by this paper
• Biliary and urinary metabolic profiles of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in the rat.

  2000cited by this paper
• Chelator‐induced iron excretion in iron‐overloaded marmosets

  2000cited by this paper
• First human studies with a high-molecular-weight iron chelator.

  2000cited by this paper
• Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.

  1999cited by this paper
• Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.

  1999cited by this paper
• Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.

  1998cited by this paper
• The Origin of the Differences in (R)‐ and (S)‐Desmethyldesferrithiocin: Iron‐Clearing Properties a

  1998cited by this paper
• Iron-chelating therapy and the treatment of thalassemia.

  1997cited by this paper
• Evaluation of new iron chelators for clinical use.

  1996cited by this paper
• Results of long-term iron-chelating therapy.

  1996cited by this paper
• Clinical experience of management of thalassemia: the Sardinian experience.

  1996cited by this paper
• Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.

  1995cited by this paper
• Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.

  1995cited by this paper
• 9 Clinical manifestations and therapy of transfusional haemosiderosis

  1994cited by this paper
• The treatment of thalassemia--slow progress and new dilemmas.

  1993cited by this paper
• Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.

  1993cited by this paper
• A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.

  1993cited by this paper
• Development of iron-chelating agents for clinical use.

  1992cited by this paper
• Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.

  1992cited by this paper
• Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning.

  1992cited by this paper
• Deferoxamine-induced bone dysplasia in patients with thalassemia major.

  1991cited by this paper
• Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.

  1991cited by this paper
• Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.

  1991cited by this paper
• Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.

  1991cited by this paper
• The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.

  1991cited by this paper
• Desferal (desferrioxamine)--a novel activator of connective tissue-type mast cells.

  1991cited by this paper
• A Comparative Evaluation of Iron Clearance Models

  1990cited by this paper
• High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation.

  1990cited by this paper
• 4 Desferrioxamine-induced iron excretion in humans

  1989cited by this paper
• Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage

  1989cited by this paper
• 11 The toxic effects of desferrioxamine

  1989cited by this paper
• Deferoxamine-induced growth retardation in patients with thalassemia major.

  1988cited by this paper
• 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.

  1987cited by this paper
• Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.

  1986cited by this paper
• Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

  1985cited by this paper
• Ferrioxamine excretion in iron-loaded man.

  1982cited by this paper
• Clinical consequences of acquired transfusional iron overload in adults.

  1981cited by this paper
• Rapid desensitisation for desferrioxamine anaphylactic reaction.

  1981cited by this paper
• Rapid desensitisation for desferrioxamine anaphylactic reaction.

  1981cited by this paper
• Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload

  1981cited by this paper
• Iron absorption in the thalassemia syndromes and its inhibition by tea.

  1979cited by this paper
• Anaphylactic reaction to desferrioxamine.

  1977cited by this paper
• Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations.

  1965cited by this paper

• Scaffold Based Search On The Desferithiocin Archetype.

  2019cites this paper
• Iron Chelators Dictate Immune Cells Inflammatory Ability: Potential Adjuvant Therapy for IBD.

  2017cites this paper
• How we manage patients with hereditary haemochromatosis

  2016cites this paper
• Chemical features of in use and in progress chelators for iron overload.

  2016cites this paper
• Recent developments centered on orally active iron chelators

  2014cites this paper
• Clinical Use of Iron Chelators

  2012cites this paper
• Chelating agents for the treatment of systemic iron overload.

  2012cites this paper
• Advances in iron chelation: an update

  2011cites this paper
• Physical growth in children with transfusion-dependent thalassemia

  2011cites this paper
• Oral iron chelators.

  2010cites this paper
• Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease.

  2009cites this paper
• Oral iron chelators.

  2008cites this paper
• Quelantes de hierro orales

  2008cites this paper